Cryoport, Inc. (NASDAQ:CYRX) Receives $11.50 Average PT from Brokerages

Shares of Cryoport, Inc. (NASDAQ:CYRX) have earned an average recommendation of “Moderate Buy” from the six analysts that are covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $11.50.

CYRX has been the subject of a number of analyst reports. Needham & Company LLC reissued a “buy” rating and set a $11.00 target price on shares of Cryoport in a research note on Wednesday, March 5th. Guggenheim initiated coverage on shares of Cryoport in a research note on Thursday, December 19th. They set a “buy” rating and a $11.00 target price for the company.

Hedge Funds Weigh In On Cryoport

A number of institutional investors and hedge funds have recently bought and sold shares of CYRX. Quest Partners LLC grew its position in Cryoport by 168.5% in the 3rd quarter. Quest Partners LLC now owns 29,083 shares of the company’s stock valued at $236,000 after buying an additional 18,252 shares in the last quarter. B. Metzler seel. Sohn & Co. Holding AG bought a new stake in Cryoport in the third quarter worth about $326,000. Intech Investment Management LLC bought a new stake in Cryoport in the third quarter worth about $105,000. Charles Schwab Investment Management Inc. raised its position in Cryoport by 0.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 387,714 shares of the company’s stock worth $3,144,000 after acquiring an additional 2,226 shares in the last quarter. Finally, Algert Global LLC raised its position in Cryoport by 282.7% in the third quarter. Algert Global LLC now owns 247,483 shares of the company’s stock worth $2,007,000 after acquiring an additional 182,808 shares in the last quarter. Institutional investors own 92.90% of the company’s stock.

Cryoport Stock Performance

CYRX stock opened at $6.41 on Thursday. Cryoport has a 1 year low of $4.58 and a 1 year high of $20.11. The stock has a market capitalization of $319.92 million, a price-to-earnings ratio of -1.90 and a beta of 1.67. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70. The stock’s fifty day moving average is $7.07 and its two-hundred day moving average is $7.48.

Cryoport (NASDAQ:CYRX) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.09). The firm had revenue of $59.53 million during the quarter, compared to the consensus estimate of $58.71 million. Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. During the same quarter in the prior year, the business earned ($0.29) earnings per share. On average, research analysts predict that Cryoport will post -0.99 EPS for the current year.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.